itraisdin 50 mg harde caps.
isdin s.a. - itraconazol 50 mg - capsule, hard - 50 mg - itraconazol 50 mg - itraconazole
itraisdin 50 mg harde caps.
isdin s.a. - itraconazol 50 mg - capsule, hard - itraconazole
itraisdin 50 mg harde caps.
isdin s.a. - itraconazol 50 mg - capsule, hard - itraconazole
betahistine viatris 8 mg tabl.
viatris gx bv-srl - betahistinedihydrochloride 8 mg - tablet - 8 mg - betahistinedihydrochloride 8 mg - betahistine
betahistine viatris 16 mg tabl.
viatris gx bv-srl - betahistinedihydrochloride 16 mg - tablet - 16 mg - betahistinedihydrochloride 16 mg - betahistine
betahistine 2hcl doc generici 16 mg, tabletten
doc generici s.r.l. via filippo turati 40 20121 milano (italiË) - betahistinedihydrochloride 16 mg/stuk samenstelling overeenkomend met ; betahistine 10,4 mg/stuk - tablet - cellulose, microkristallijn (e 460) ; crospovidon (e 1202) ; lactose 1-water ; povidon (e 1201) ; siliciumdioxide (e 551) ; stearinezuur (e 570), - betahistine
betahistine 2hcl doc generici 8 mg, tabletten
doc generici s.r.l. via filippo turati 40 20121 milano (italiË) - betahistinedihydrochloride 8 mg/stuk samenstelling overeenkomend met ; betahistine 5,2 mg/stuk - tablet - cellulose, microkristallijn (e 460) ; crospovidon (e 1202) ; lactose 1-water ; povidon (e 1201) ; siliciumdioxide (e 551) ; stearinezuur (e 570), - betahistine
betahistine viatris 24 mg tabl.
viatris gx bv-srl - betahistinedihydrochloride 24 mg - tablet - 24 mg - betahistinedihydrochloride 24 mg - betahistine
azacitidine betapharm
betapharm arzneimittel gmbh - azacitidine - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastische middelen - azacitidine betapharm is geïndiceerd voor de behandeling van volwassen patiënten die niet in aanmerking komen voor hematopoëtische stamceltransplantatie (hsct) met:intermediate-2 en hoog-risico myelodysplastische syndromen (mds) volgens de international prognostic scoring system (ipss),chronische myelomonocytic leukemie (van cmml) met 10 % naar 29 % van het beenmerg ontploffing zonder myeloproliferatieve stoornis,acute myeloïde leukemie (aml) met 20% tot 30 % ontploffing en multi-geslacht dysplasie, volgens de world health organization (who) classificatie,aml met > 30 % beenmerg ontploffing volgens de who-classificatie.
azacitidine mylan
mylan ireland limited - azacitidine - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastische middelen - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.